PDS Biotechnology (NASDAQ:PDSB) Announces Earnings Results

PDS Biotechnology (NASDAQ:PDSB) released its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06, FiscalAI reports.

Here are the key takeaways from PDS Biotechnology’s conference call:

• The company amended VERSATILE-003 to make PFS an earlier interim primary endpoint after the FDA raised no objections, aiming to shorten trial duration and enable a potential accelerated approval with a PFS readout expected in about 1–1.5 years.
• Final VERSATILE-002 topline showed a median overall survival of 39.3 months in PD-L1 CPS ≥1 patients, which management cites as robust evidence supporting the phase III amendment and durable clinical benefit.
• Early NCI-led data for PDS-01ADC plus docetaxel in metastatic castration-resistant prostate cancer reported a median PFS of 9.6 months and a median PSA decline of 40% (6 of 16 patients >50% PSA decline), reinforcing the program’s potential across solid tumors.
• The company secured new U.S. and Japanese patents for PDS0101 and expects biologics exclusivity, which together extend market protection into the 2040s and strengthen the intellectual property estate.
• Financially, PDS reported a 2025 net loss of $34.5 million and held $26.7 million in cash at year-end, a level that may pressure runway and necessitate additional financing.

PDS Biotechnology Trading Up 12.8%

Shares of PDSB opened at $0.61 on Wednesday. The firm’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.85. The firm has a market capitalization of $31.68 million, a P/E ratio of -0.81 and a beta of 1.20. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. PDS Biotechnology has a twelve month low of $0.51 and a twelve month high of $1.92.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the 4th quarter valued at $25,000. Geode Capital Management LLC boosted its stake in shares of PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after acquiring an additional 38,399 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of PDS Biotechnology during the second quarter valued at $91,000. Jane Street Group LLC purchased a new stake in PDS Biotechnology during the 2nd quarter worth about $92,000. Finally, Susquehanna International Group LLP increased its position in PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.